Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide, with limited curative options. Tumor vaccines activate the immune system against malignant cells and represent a promising approach. Multiple platforms – peptide, dendritic cell (DC), nucleic acid (DNA/mRNA), and viral vector – have been explored. Peptide and DC vaccines have the most clinical data, showing safety and immunogenicity. Personalized neoantigen vaccines are refining precision. Major challenges include an immunosuppressive tumor microenvironment, heterogeneity, immune evasion, and weak immunogenicity. Advances in sequencing, nanotechnology, and AI are opening new avenues. Combinations with immune checkpoint inhibitors (ICIs), chemotherapy, or locoregional treatments are under active investigation. Vaccine‑based immunotherapy for HCC is still early but holds great potential.
Introduction
HCC is the sixth most common cancer and third leading cause of cancer death globally; China bears nearly 45% of the burden. Only ~40% of patients are eligible for curative therapy at diagnosis, and 5‑year survival is only 14.8%. Immunotherapy is now first‑line for advanced HCC, and tumor vaccines have emerged as a new therapeutic avenue.
Antigen Selection and Vaccine Design
Tumor antigens are tumor‑associated (TAAs: AFP, DCP, GPC3) or tumor‑specific (TSAs: neoantigens). TAAs are overexpressed but have limited specificity. TSAs arise from somatic mutations, show high specificity and immunogenicity, and enable personalized therapeutic cancer vaccines (PTCVs) identified via high‑throughput sequencing and bioinformatics.
Vaccine Platforms
Peptide vaccines : High specificity, easy to manufacture. AFP/GPC3 peptides induced immune responses with no severe toxicity. Personalized peptide vaccine improved recurrence‑free survival. Weak immunogenicity often requires adjuvants.
Nucleic acid vaccines (DNA/mRNA) : Flexible, encode full antigens. AFP DNA vaccine was safe. GNOS‑PV02 (personalized neoantigen DNA) + pembrolizumab achieved 30.6% objective responses. mRNA vaccines in early trials; delivery remains challenging.
Viral vector vaccines : Strong immunogenicity but limited by pre‑existing immunity and safety concerns.
DC vaccines : Most clinically advanced. Tumor lysate‑ or antigen‑pulsed DCs show safety and immune responses, but manufacturing complexity and high costs limit widespread use.
Clinical and Preclinical Evidence
Most HCC vaccine studies are phase I/II, small, and heterogeneous. Recent trials shift toward nucleic acid platforms and PTCVs. Combinations with ICIs or locoregional therapies are increasingly common, with early efficacy signals. Standardized staging, biomarker integration, and survival endpoints are lacking.
Barriers to Clinical Translation
Immunosuppressive TIME : Tregs, MDSCs, TAMs suppress CTL/NK activity.
Heterogeneity : Inter‑ and intratumoral variability leads to inconsistent responses.
Resistance and evasion : Epigenetic changes, PD‑L1 upregulation, and immunosuppressive cytokines (TGF‑β, IL‑10) enable immune escape.
Regulatory gaps : No formal guidelines; most trials exploratory; lack of standardized dosing, timing, and delivery.
Future Directions
Combination strategies : Vaccines + ICIs are most promising. Chemotherapy/radiotherapy induce tumor apoptosis, releasing TAAs. Cyclophosphamide depletes Tregs; CSF1R/CCR2 inhibitors reduce immunosuppressive myeloid cells.
Personalized vaccines : PTCVs using patient‑specific neoantigens are a central focus. Computational algorithms predict immunogenic mutations. Ongoing trials; high costs and long manufacturing remain obstacles.
Emerging technologies : LNPs enhance delivery; synthetic biology designs novel adjuvants; CRISPR/Cas9 modifies tumor genes; AI aids neoantigen prediction. Advanced preclinical models (fibrotic HCC models, humanized mice, organoids) better recapitulate human disease.
Conclusions
Cancer vaccines hold promise for HCC. Peptide and DC vaccines have shown feasibility but limited efficacy. The field is shifting toward DNA/mRNA platforms and PTCVs. Most trials are early; larger studies and longer follow‑up are needed. Future focus on combinations, PTCV optimization, and AI integration. Despite challenges, multimodal vaccine‑based strategies offer potential for more precise and effective HCC treatment.
Full text
https://www.xiahepublishing.com/2310-8819/JCTH-2025-00401
The study was recently published in the Journal of Clinical and Translational Hepatology .
The Journal of Clinical and Translational Hepatology (JCTH) is owned by the Second Affiliated Hospital of Chongqing Medical University and published by XIA & HE Publishing Inc. JCTH publishes high quality, peer reviewed studies in the translational and clinical human health sciences of liver diseases. JCTH has established high standards for publication of original research, which are characterized by a study’s novelty, quality, and ethical conduct in the scientific process as well as in the communication of the research findings. Each issue includes articles by leading authorities on topics in hepatology that are germane to the most current challenges in the field. Special features include reports on the latest advances in drug development and technology that are relevant to liver diseases. Regular features of JCTH also include editorials, correspondences and invited commentaries on rapidly progressing areas in hepatology. All articles published by JCTH, both solicited and unsolicited, must pass our rigorous peer review process.
Follow us on X: @xiahepublishing
Follow us on LinkedIn: Xia & He Publishing Inc.
Journal of Clinical and Translational Hepatology
Tumor Vaccines in Hepatocellular Carcinoma: Advances, Challenges, and the Path Toward Precision Immunotherapy
19-Jan-2026